We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . More info . X close

ASEAN Point of Care Diagnostics Market: Growth, Size, Share, and Trends

Report Code MD 8010
Published in May, 2025, By MarketsandMarkets™
Download PDF

Choose License Type

Buy Report Now Inquire Before Buying

ASEAN Point of Care Diagnostics Market by Product (Infectious Disease (TB, Hepatitis, STDs, HAIs), Glucose, Cardiometabolic, Pregnancy, Coagulation), Technology (Lateral Flow Assays, Biochemistry, MDx), End User (Home Care, Hospitals) - Forecast to 2030

Overview

The global ASEAN point of care diagnostics market, valued at US$1.05 billion in 2024, is forecasted to grow at a robust CAGR of 4.7%, reaching US$1.08 billion in 2025 and an impressive US$1.36 billion by 2030. The increasing incidence of chronic conditions, especially diabetes, generates the demand for regular monitoring and early detection, boosting the need for rapid & accurate POC testing solutions. Devices like glucose monitors are increasingly being used for their capability to provide fast results, allowing patients to manage their conditions effectively and facilitating timely medical intervention. Furthermore, government efforts to improve the accessibility of healthcare and promote innovation in diagnostic technologies are also driving market growth. The increasing number of public-private partnerships (PPPs) in the region further drives the development, distribution, and use of point of care diagnostic products.

Asean Point of Care Diagnostics Market– Global Forecast and Key Opportunities to 2030

Attractive Opportunities in the Asean Point of Care Diagnostics Market

VIETNAM

Vietnam's high growth rate can be attributed to the strong government inclination to strengthen primary care and screening programs, which has accelerated the integration of POC devices into both public and private healthcare systems.

The growth of the ASEAN point of care diagnostics market is driven by the growing incidence of infectious diseases and primary chronic conditions, favorable government initiatives, and heavy public & private investments.

Emerging markets and expanding healthcare access in rural and semi-urban areas are expected to offer growth opportunities for market players during the forecast period.

The Vietnam point of care diagnostics market is expected to be worth USD 188.5 million by 2030, growing at a CAGR of 5.9% during the forecast period.

Product approvals and partnerships were the most widely adopted growth strategies by market players.

Global Asean Point of Care Diagnostics Market Dynamics

DRIVER: Rising incidence of infectious diseases

The increasing incidence of infectious diseases is a significant driver of growth in Southeast Asia's point-of-care (POC) diagnostics market (ASEAN). The region faces various health challenges, including respiratory infections, sexually transmitted diseases, tropical diseases, and emerging viral outbreaks. The demand for early diagnosis and timely medical intervention has made POC diagnostics essential, offering quick and reliable results at or near the patient. This approach reduces delays commonly associated with laboratory-based centralized testing. In several ASEAN countries, where healthcare infrastructure is still developing and access to diagnostic facilities can vary greatly, POC testing is crucial in improving infectious disease control. The availability of highly sensitive and specific tests enables early diagnosis and treatment and helps minimize disease transmission, ultimately leading to better public health outcomes across the region.

RESTRAINT: Stringent regulatory approval processes for product commercialization

Regulatory approval pathways for point of care diagnostics in ASEAN nations can be highly challenging for manufacturers, serving generally as a barrier to the pace and efficiency of product commercialization. Although the ASEAN Medical Device Directive (AMDD) was implemented to harmonize the regulation of medical devices among member states, the actual application of these guidelines remains country-specific. Before marketing POC diagnostic products, they are subjected to thorough conformity assessments and approved by the appropriate national regulatory bodies. Inconsistencies between local regulatory interpretations, documentation, clinical performance expectations, and approval schedules may create inconsistencies in the region. This complicates manufacturing firms' ability to pursue a consistent market entry strategy and tends to cause delays, create more administrative burdens, and incur more regulatory compliance expenses.

 

OPPORTUNITY: Growing adoption of multiplex POC testing solutions

The growing availability of multiplex POC diagnostic tests is expected to create opportunities for market growth in the ASEAN market. Advanced tests allow for the simultaneous detection of multiple pathogens or biomarkers from a single sample, improving diagnostic speed and accuracy, especially for diseases like respiratory infections. Multiplex point-of-care (POC) tests help healthcare professionals manage cases more effectively by reducing the need for repeat testing, lowering costs, and increasing diagnostic efficiency. As ASEAN countries continue to enhance their healthcare systems, the demand for such efficient and timely solutions is expected to grow. Additionally, partnerships between diagnostic companies and international health organizations are expanding access to multiplex testing across the region, addressing some of the most pressing healthcare challenges in urban and rural areas. Moreover, market players invest in developing a multiplex platform to address the increasing clinical demand. For instance, in January 2025, Roche (Switzerland) gained the US FDA 510(k) clearance and CLIA waiver for its cobas liat sexually transmitted infection (STI) multiplex assay, reflecting continued progress in this area. Such developments indicate a favorable future for multiplex POC test adoption in ASEAN healthcare systems.

CHALLENGES: Limited availability of skilled healthcare professionals

Shortage of skilled healthcare professionals is a chronic challenge that affects the adoption and effective utilization of point of care diagnostics in ASEAN nations. Many healthcare facilities, particularly those in rural and remote areas, often lack trained personnel who can confidently use point-of-care (POC) devices and accurately interpret their results. Although POC testing aims to streamline and expedite diagnosis, its effectiveness relies heavily on proper handling—from specimen collection and preparation to result interpretation. Without experienced staff, there is a greater risk of inaccurate readings and delayed decision-making, which can negatively impact patient care and treatment outcomes.

This skills gap is especially pronounced in countries with rapidly growing populations, where healthcare systems are challenged to keep up with increasing patient volumes while facing limited human resources. To fully realize the benefits of POC diagnostics for early detection and improved healthcare delivery in the ASEAN region, it is essential to bridge this skills gap through targeted training and workforce development initiatives.

Global Asean Point of Care Diagnostics Market Ecosystem Analysis

The ASEAN point of care diagnostics market operates within a diverse ecosystem involving various stakeholders. The market includes a wide range of products, such as infectious disease testing products, glucose monitoring products, cardiometabolic tests, and coagulation monitoring devices, which are widely used across hospitals, outpatient settings, and clinical laboratories. Manufacturers focus on product development and performance optimization, while distribution is handled through third-party vendors and online platforms. The ecosystem is shaped by patients, healthcare providers, investors, and regulatory bodies, all playing vital roles in driving market growth and adoption.

Asean Point of Care Diagnostics Market
 

In 2024, the glucose monitoring products segment accounted for the largest share of the market, by product.

Based on product, the ASEAN point of care diagnostics market is segmented into infectious disease testing products, glucose monitoring products, cardiometabolic testing products, coagulation monitoring products, pregnancy & fertility testing products, urinalysis testing products, cancer marker testing products, cholesterol testing products, hematology testing products, fecal occult testing products, drugs-of-abuse testing products, and other POC products.

The glucose monitoring products segment accounted for the largest share of the point of care diagnostics market. The dominance of this segment is primarily due to the increasing incidence of diabetes in ASEAN nations and the growing focus on regular blood glucose management, both in clinical & home care settings. The convenience, precision, and real-time results provided by glucose monitoring devices make them critical in diabetes care for both early detection & disease management. Moreover, heightened patient awareness, government initiatives to control diabetes, and the rising adoption of easy-to-use glucose monitoring solutions continue to drive the dominance of the segment in the point of care diagnostics market.

By technology, the rapid tests (molecular diagnostics) segment is expected to grow at the highest CAGR during the forecast period.

The ASEAN point of care diagnostics market can be segmented based on technology into lateral flow assays (immunoassays), rapid tests (molecular diagnostics), and biochemistry. The rapid tests segment is expected to grow at the highest CAGR in the market during the forecast period. The increasing requirement for quick, precise, and efficient diagnostic solutions, particularly for infectious diseases, drives the demand for molecular-based rapid tests. Such tests have the advantage of being sensitive and possessing rapid turnaround times, proving increasingly popular across clinical and near-patient care facilities. Ongoing advancement in portable molecular platforms, coupled with an increasing emphasis on early and accurate disease diagnosis, is set to strengthen the growth of this technology segment further across ASEAN nations.

In 2024, Indonesia accounted for the largest share of the ASEAN point of care diagnostics market.

The ASEAN point of care diagnostics market is divided into ten countries: Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei. In 2024, Indonesia emerged as the ASEAN region's leading POC diagnostics market. Indonesia's increasing population, combined with the rising burden of infectious & chronic conditions, has primarily fueled the need for affordable and effective diagnostic services. The expansion of healthcare services has further propelled the use of point of care testing at a faster pace, providing quicker diagnosis in areas where the laboratory setup is limited. Furthermore, the government's focus on improving early disease detection and strengthening primary health through public health campaigns has further aided market growth. Increased healthcare spending, insurance coverage, and access to low-cost POC diagnostic instrumentation have played a key role in positioning Indonesia at the forefront of the ASEAN market.

LARGEST MARKET SHARE IN 2024
INDONESIA: LARGEST MARKET IN THE REGION
Asean Point of Care Diagnostics Market

Recent Developments of Asean Point of Care Diagnostics Market

  • In January 2025, bioMérieux (France) entered into an agreement to acquire SpinChip (Norway), which has developed an immunoassay diagnostics platform. The small benchtop analyzer is well-adapted for near-patient testing. It can deliver a result from a whole blood sample within 10 minutes with the same high-sensitivity performance as the laboratory instruments.
  • In January 2025, the US FDA granted F. Hoffmann-La Roche Ltd. (Switzerland) 510(k) clearance and Clinical Laboratory Improvement Amendments of 1988 (CLIA) for its cobas liat sexually transmitted infection (STI) multiplex assay panels. These panels diagnose sexually transmitted infections at the point of care.
  • In December 2024, bioMérieux (France) revealed that the BIOFIRE FILMARRAY Gastrointestinal (GI) Panel Mid has obtained clearance from the US FDA. This midplex molecular panel tests 11 of the most common bacteria, viruses, and parasites associated with gastroenteritis—all from one sample, with results available in approximately one hour.
  • In June 2024, F. Hoffmann-La Roche Ltd. (Switzerland) acquired LumiraDx’s (US) Point of Care technology to expand its offering in decentralized patient care further and drive global access to timely and actionable diagnostic results.

Key Market Players

Want to explore hidden markets that can drive new revenue in ASEAN Point of Care Diagnostics Market?

Scope of the Report

Report Metric Details
Market size available for years 2022-2030
Base Year Considered 2024
Forecast period 2025-2030
Forecast units Value (USD)
Segments covered Product, Technology, and End User
Geographies covered Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei

Frequently Asked Questions (FAQ)

What recent trends affect the ASEAN point of care diagnostics market?

Recent trends affecting the ASEAN point of care diagnostics market involve ongoing technological advancements, the rising need for quick & precise testing, and the growing focus on patient-centric healthcare. Rising government investments in healthcare infrastructure further support the production & uptake of POC tests, enhancing availability and reducing test costs throughout the region.

Who are the key players in the ASEAN point of care diagnostics market?

The key players in this market are Abbott (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Sysmex Corporation (Japan), Danaher Corporation (US), BD (US), QuidelOrtho Corporation (US), Cardinal Health (US), AccuBioTech Co., Ltd. (China), EKF Diagnostics Holdings plc (UK), bioMérieux (France), and Thermo Fisher Scientific Inc. (US).

Who are the primary end users of point of care diagnostic products?

Based on end users, the ASEAN point of care diagnostics market is segmented into clinical laboratories, hospitals and critical care centers, outpatient settings and ambulatory care centers, home care settings, and other end users. Home care settings dominated the market due to the increasing demand for affordable, convenient, and personalized healthcare products.

What are the opportunities for growth in the ASEAN point of care diagnostics market?

The ASEAN point of care diagnostics market provides various growth prospects, such as a steady inclination toward decentralized healthcare systems, which is driving the demand for rapid & portable diagnostic products. Additionally, the growing adoption of multiplex POC tests, which can identify multiple conditions from a single sample, enhances diagnostic effectiveness and facilitates wider usage in clinical and remote environments.

Which country is lucrative for the ASEAN point of care diagnostics market?

Vietnam is one of the most promising countries in the ASEAN point-of-care diagnostics market, primarily due to its expanding healthcare infrastructure, increased healthcare expenditures, government initiatives to improve access to healthcare, and awareness of early diagnosis benefits.

Personalize This Research

  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
Request A Free Customisation

Let Us Help You

  • What are the Known and Unknown Adjacencies Impacting the ASEAN Point of Care Diagnostics Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
Customized Workshop Request

Table of Contents

Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.

TITLE
PAGE NO
INTRODUCTION
27
RESEARCH METHODOLOGY
32
EXECUTIVE SUMMARY
45
PREMIUM INSIGHTS
49
MARKET OVERVIEW
52
  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    DRIVERS
    - Rising incidence of infectious diseases
    - Increasing prevalence of chronic diseases
    - Favorable government initiatives for POC testing
    - Rising number of public-private partnerships (PPPs)
    RESTRAINTS
    - Pricing pressure on manufacturers
    - Stringent regulatory approval process for product commercialization
    OPPORTUNITIES
    - Gradual shift toward decentralized healthcare systems
    - Availability of POC tests with multiplexing capabilities
    CHALLENGES
    - Shortage of skilled healthcare providers
    - Premium pricing of novel platforms
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • 5.4 PRICING ANALYSIS
    INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT
    INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER
    INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY
  • 5.5 VALUE CHAIN ANALYSIS
  • 5.6 SUPPLY CHAIN ANALYSIS
  • 5.7 ECOSYSTEM ANALYSIS
  • 5.8 INVESTMENT & FUNDING SCENARIO
  • 5.9 TECHNOLOGY ANALYSIS
    KEY TECHNOLOGIES
    - Lateral flow assays
    COMPLEMENTARY TECHNOLOGIES
    - Molecular diagnostics
    ADJACENT TECHNOLOGIES
    - Biochemical technologies
  • 5.10 PATENT ANALYSIS
  • 5.11 TRADE ANALYSIS
    IMPORT DATA FOR HS CODE 3822
    EXPORT DATA FOR HS CODE 3822
  • 5.12 KEY CONFERENCES & EVENTS, 2025–2026
  • 5.13 REGULATORY ANALYSIS
    REGULATORY LANDSCAPE
    - Vietnam
    - Laos
    - Cambodia
    - Malaysia
    - Myanmar
    - Philippines
    - Singapore
    - Thailand
    - Indonesia
    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.14 PORTER’S FIVE FORCES ANALYSIS
    THREAT OF NEW ENTRANTS
    THREAT OF SUBSTITUTES
    BARGAINING POWER OF BUYERS
    BARGAINING POWER OF SUPPLIERS
    INTENSITY OF COMPETITIVE RIVALRY
  • 5.15 KEY STAKEHOLDERS & BUYING CRITERIA
    KEY STAKEHOLDERS IN BUYING PROCESS
    KEY BUYING CRITERIA
  • 5.16 IMPACT OF AI ON ASEAN POINT OF CARE DIAGNOSTICS MARKET
    INTRODUCTION
    MARKET POTENTIAL OF AI IN POC DIAGNOSTIC APPLICATIONS
    AI USE CASES
    KEY COMPANIES IMPLEMENTING AI
    FUTURE OF AI IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT
89
  • 6.1 INTRODUCTION
  • 6.2 GLUCOSE MONITORING PRODUCTS
    GLUCOMETERS
    - Accurate monitoring of blood sugar levels to drive market
    GLUCOSE TEST STRIPS
    - Increasing uptake of single-use products to fuel market
    LANCETS
    - Increasing preference for home-based care to support market growth
  • 6.3 INFECTIOUS DISEASE TESTING PRODUCTS
    RESPIRATORY INFECTION TESTING PRODUCTS
    - TB testing products
    - Influenza testing products
    - Other respiratory infection testing products
    MOSQUITO-BORNE DISEASE TESTING PRODUCTS
    - Rising incidence of malaria & dengue to boost demand
    STD TESTING PRODUCTS
    - Need to reduce disease transmission rates to facilitate growth
    HIV TESTING PRODUCTS
    - Growing awareness of HIV POC testing to boost demand
    HAI TESTING PRODUCTS
    - Growing incidence of HAIs in healthcare settings to drive market
    HEPATITIS TESTING PRODUCTS
    - Hepatitis B testing products
    - Hepatitis C testing products
    OTHER INFECTIOUS DISEASE TESTING PRODUCTS
  • 6.4 COVID-19 TESTING PRODUCTS
    GRADUAL SHIFT TOWARDS SYNDROMIC TESTING TO SUPPORT MARKET GROWTH
  • 6.5 CARDIOMETABOLIC TESTING PRODUCTS
    CARDIAC MARKER TESTING PRODUCTS
    - Early detection of myocardial infarctions and acute coronary syndromes to fuel market
    HBA1C TESTING PRODUCTS
    - Provision of long-term measurement in blood glucose control to boost demand
    BLOOD GAS & ELECTROLYTE TESTING PRODUCTS
    - Monitoring of key parameters for pH and oxygen saturation to drive market
  • 6.6 COAGULATION MONITORING PRODUCTS
    HIGH INCIDENCE OF BLEEDING DISORDERS TO FUEL UPTAKE
  • 6.7 PREGNANCY & FERTILITY TESTING PRODUCTS
    GROWING AWARENESS OF SUSTAINABLE FAMILY PLANNING TO PROPEL MARKET
  • 6.8 HEMATOLOGY TESTING PRODUCTS
    RISING DEMAND FOR BLOOD TRANSFUSION PROCEDURES TO DRIVE MARKET
  • 6.9 CANCER MARKER TESTING PRODUCTS
    INCREASING PREFERENCE FOR PERSONALIZED ONCOLOGY THERAPEUTICS TO PROPEL MARKET
  • 6.10 FECAL OCCULT TESTING PRODUCTS
    FAVORABLE INITIATIVES FOR COLORECTAL CANCER SCREENING TO BOOST MARKET
  • 6.11 CHOLESTEROL TESTING PRODUCTS
    RISING OBESITY RATE CAUSED BY SEDENTARY LIFESTYLES TO DRIVE MARKET
  • 6.12 URINALYSIS TESTING PRODUCTS
    RISING PREVALENCE OF UTIS AND KIDNEY DISEASES TO DRIVE MARKET
  • 6.13 DRUGS-OF-ABUSE TESTING PRODUCTS
    HIGH CONSUMPTION OF ILLICIT DRUGS TO FUEL MARKET
  • 6.14 OTHER POC PRODUCTS
ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY
151
  • 7.1 INTRODUCTION
  • 7.2 BIOCHEMISTRY
    PROVISION OF RAPID ONSITE RESULTS FOR CHRONIC CONDITIONS TO DRIVE MARKET
  • 7.3 LATERAL FLOW ASSAYS (IMMUNOASSAYS)
    INTEGRATION OF ELISA INTO DISPOSABLE TESTING STRIPS FOR COMPLEX LABORATORY ANALYSIS TO FUEL MARKET
  • 7.4 RAPID TESTS (MOLECULAR DIAGNOSTICS)
    ANALYSIS OF BIOLOGICAL MARKERS FOR RAPID DISEASE DETECTION TO PROPEL MARKET
ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER
159
  • 8.1 INTRODUCTION
  • 8.2 HOME CARE SETTINGS
    GROWING CONSUMER PREFERENCE FOR CONVENIENCE AND AFFORDABILITY TO PROPEL MARKET
  • 8.3 CLINICAL LABORATORIES
    MANAGEMENT OF HIGH PATIENT VOLUMES WITH AUTOMATED TESTING SOLUTIONS TO FUEL MARKET
  • 8.4 HOSPITALS AND CRITICAL CARE CENTERS
    RISING REQUIREMENT FOR RAPID POC TESTING IN EMERGENCY USE TO SUPPORT MARKET GROWTH
  • 8.5 OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS
    COST-EFFECTIVENESS OVER HOSPITALS TO BOOST MARKET GROWTH
  • 8.6 OTHER END USERS
ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY
168
  • 9.1 INTRODUCTION
    MACROECONOMIC OUTLOOK FOR ASEAN COUNTRIES
  • 9.2 INDONESIA
    RISING PUBLIC AWARENESS ABOUT PREVENTIVE HEALTHCARE TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR INDONESIA
  • 9.3 THAILAND
    EXPANDING GERIATRIC POPULATION AND SUBSEQUENT RISE IN CHRONIC DISEASES TO FUEL MARKET
    MACROECONOMIC OUTLOOK FOR THAILAND
  • 9.4 MALAYSIA
    HIGH INCIDENCE OF DIABETES TO BOOST DEMAND
    MACROECONOMIC OUTLOOK FOR MALAYSIA
  • 9.5 PHILIPPINES
    IMPROVED HEALTHCARE ACCESS AND INSURANCE COVERAGE TO FUEL ADOPTION
    MACROECONOMIC OUTLOOK FOR PHILIPPINES
  • 9.6 VIETNAM
    IMPROVING HEALTHCARE INFRASTRUCTURE AND FAVORABLE GOVERNMENT INITIATIVES TO PROPEL MARKET
    MACROECONOMIC OUTLOOK FOR VIETNAM
  • 9.7 SINGAPORE
    INCREASING DEMAND FOR SPECIALIZED MEDICAL SERVICES TO BOOST MARKET
    MACROECONOMIC OUTLOOK FOR SINGAPORE
  • 9.8 MYANMAR
    RISING NEED FOR AFFORDABLE DIAGNOSTIC SOLUTIONS TO DRIVE MARKET
    MACROECONOMIC OUTLOOK FOR MYANMAR
  • 9.9 CAMBODIA
    RISING PREVALENCE OF NCDS TO SUPPORT MARKET GROWTH
    MACROECONOMIC OUTLOOK FOR CAMBODIA
  • 9.10 LAOS
    NEED FOR DECENTRALIZED DIAGNOSTIC SOLUTIONS TO FUEL DEMAND
    MACROECONOMIC OUTLOOK FOR LAOS
  • 9.11 BRUNEI
    GROWING NEED FOR COST-EFFECTIVE POC SOLUTIONS TO FUEL MARKET
    MACROECONOMIC OUTLOOK FOR BRUNEI
COMPETITIVE LANDSCAPE
233
  • 10.1 INTRODUCTION
  • 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • 10.3 REVENUE ANALYSIS, 2022–2024
  • 10.4 MARKET SHARE ANALYSIS, 2024
  • 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    STARS
    EMERGING LEADERS
    PERVASIVE PLAYERS
    PARTICIPANTS
    COMPANY FOOTPRINT, KEY PLAYERS, 2024
    - Company footprint
    - Country footprint
    - Product footprint
    - Technology footprint
  • 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    PROGRESSIVE COMPANIES
    RESPONSIVE COMPANIES
    DYNAMIC COMPANIES
    STARTING BLOCKS
    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    - Detailed list of key startups/SMEs
    - Competitive benchmarking of key startups/SMEs, by technology
    - Competitive benchmarking of key startups/SMEs, by country
  • 10.7 COMPANY VALUATION & FINANCIAL METRICS
    FINANCIAL METRICS
    COMPANY VALUATION
  • 10.8 BRAND/PRODUCT COMPARISON
  • 10.9 COMPETITIVE SCENARIO
    PRODUCT LAUNCHES & APPROVALS
    DEALS
    EXPANSIONS
COMPANY PROFILES
254
  • 11.1 KEY PLAYERS
    ABBOTT
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    F. HOFFMANN-LA ROCHE LTD.
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SIEMENS HEALTHINEERS AG
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    SYSMEX CORPORATION
    - Business overview
    - Products offered
    - Recent developments
    - MnM view
    DANAHER CORPORATION
    - Business overview
    - Products offered
    - MnM view
    BD
    - Business overview
    - Products offered
    - Recent developments
    QUIDELORTHO CORPORATION
    - Business overview
    - Recent developments
    CARDINAL HEALTH
    - Business overview
    - Products offered
    - Recent developments
    BIOMÉRIEUX
    - Business overview
    - Products offered
    - Recent developments
    EKF DIAGNOSTICS HOLDINGS PLC
    - Business overview
    - Products offered
    - Recent developments
    THERMO FISHER SCIENTIFIC INC.
    - Business overview
    - Products offered
    - Recent developments
    ACCUBIOTECH, CO., LTD.
    - Business overview
    - Products offered
    - Recent developments
  • 11.2 OTHER PLAYERS
    BIOSYNEX SA
    SD BIOSENSOR, INC.
    SEKISUI DIAGNOSTICS
    WERFEN
    TRINITY BIOTECH
    PTS DIAGNOSTICS
    LIFESCAN IP HOLDINGS, LLC
    CTK BIOTECH, INC.
    WONDFO
    ARKRAY, INC.
    XIAMEN BOSON BIOTECH CO., LTD.
    CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.
    ANBIO BIOTECHNOLOGY INC.
    SG DIAGNOSTICS
APPENDIX
326
  • 12.1 DISCUSSION GUIDE
  • 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
  • 12.3 AVAILABLE CUSTOMIZATIONS
  • 12.4 RELATED REPORTS
  • 12.5 AUTHOR DETAILS
LIST OF TABLES
 
  • TABLE 1 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY DATA FROM PRIMARY SOURCES
  • TABLE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RISK ASSESSMENT ANALYSIS
  • TABLE 3 HEPATITIS DISEASE BURDEN AND DEATHS CAUSED BY HEPATITIS, BY COUNTRY (2022)
  • TABLE 4 DIABETES ESTIMATES (AGES 20–79) AND DIABETES-RELATED DEATHS, BY COUNTRY, 2021
  • TABLE 5 PROJECTED INCREASE IN CANCER PATIENTS, BY COUNTRY, 2022 VS. 2035 VS. 2045
  • TABLE 6 INDICATIVE SELLING PRICE TREND OF POC TESTS, BY PRODUCT, 2023–2025
  • TABLE 7 INDICATIVE SELLING PRICE TREND OF GLUCOSE TEST STRIPS, BY KEY PLAYER, 2023−2025
  • TABLE 8 INDICATIVE SELLING PRICE TREND OF POC PREGNANCY TEST KITS, BY COUNTRY, 2023–2025
  • TABLE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ROLE IN ECOSYSTEM
  • TABLE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: INNOVATIONS & PATENT REGISTRATIONS, 2022–2024
  • TABLE 11 IMPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 12 EXPORT DATA FOR DIAGNOSTIC & LABORATORY REAGENTS (HS CODE 3822), BY COUNTRY, 2020–2024 (USD THOUSAND)
  • TABLE 13 ASEAN POC DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2025–2026
  • TABLE 14 MALAYSIA: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 15 MYANMAR: CLASSIFICATION OF IVD MEDICAL DEVICES
  • TABLE 16 ASEAN COUNTRIES: KEY REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY (%)
  • TABLE 19 KEY BUYING CRITERIA, BY TECHNOLOGY
  • TABLE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 21 DIABETES PREVALENCE (20–79 YRS), DIABETES-RELATED DEATHS, AND PROPORTION OF UNDIAGNOSED DIABETES, BY COUNTRY, 2021
  • TABLE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 24 GLUCOMETERS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOMETERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 26 GLUCOSE TEST STRIPS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE TEST STRIPS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 28 LANCETS & LANCING DEVICES: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 29 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LANCETS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 30 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 32 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 33 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 34 TB TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR TB TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 36 INFLUENZA TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFLUENZA TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 38 OTHER RESPIRATORY INFECTION TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 39 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER RESPIRATORY INFECTION TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 40 MOSQUITO-BORNE DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 41 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR MOSQUITO-BORNE DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 42 STD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 43 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR STD TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 44 HIV TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 45 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HIV TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 46 HAI TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 47 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HAI TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 48 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 49 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 50 HEPATITIS B TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 51 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS B TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 52 HEPATITIS C TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 53 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 54 OTHER INFECTIOUS DISEASE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 55 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER INFECTIOUS DISEASE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 56 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COVID-19 TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 57 CARDIOMETABOLIC TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 58 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 59 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 60 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIAC MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 61 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HBA1C TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 62 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BLOOD GAS & ELECTROLYTE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 63 COAGULATION MONITORING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 64 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR COAGULATION MONITORING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 65 PREGNANCY & FERTILITY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 66 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR PREGNANCY & FERTILITY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 67 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOTAL NUMBER OF PREGNANCIES, BY COUNTRY, 2022−2030 (IN MILLION)
  • TABLE 68 HEMATOLOGY TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 69 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEMATOLOGY TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 70 NUMBER OF CASES FOR TOP FIVE CANCER TYPES, 2022
  • TABLE 71 CANCER MARKER TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 72 ASEAN POINT OF CARE DIAGNOSTICS MARKET OF CANCER MARKER TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 73 ESTIMATED NUMBER OF NEW CASES OF COLORECTAL CANCER, 2022 VS. 2035 VS. 2045
  • TABLE 74 FECAL OCCULT BLOOD TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 75 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR FECAL OCCULT BLOOD TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 76 CHOLESTEROL TESTING PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 77 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CHOLESTEROL TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 78 URINALYSIS TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 79 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR URINALYSIS TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 80 DRUGS-OF-ABUSE TESTING: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 81 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR DRUGS-OF-ABUSE TESTING PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 82 OTHER POC PRODUCTS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 83 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER POC PRODUCTS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 84 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 85 BIOCHEMISTRY: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 86 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR BIOCHEMISTRY, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 87 LATERAL FLOW ASSAYS: CURRENTLY AVAILABLE PRODUCTS, BY COMPANY
  • TABLE 88 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR LATERAL FLOW ASSAYS (IMMUNOASSAYS), BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 89 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RAPID TESTS (MOLECULAR DIAGNOSTICS), BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 90 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 91 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOME CARE SETTINGS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 92 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CLINICAL LABORATORIES, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 93 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HOSPITALS AND CRITICAL CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 94 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OUTPATIENT SETTINGS AND AMBULATORY CARE CENTERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 95 ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR OTHER END USERS, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 96 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2022–2030 (USD MILLION)
  • TABLE 97 INDONESIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 98 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 99 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 100 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 101 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 102 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 103 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 104 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 105 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 106 INDONESIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 107 THAILAND: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 108 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 109 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 110 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 111 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 112 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 113 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 114 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 115 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 116 THAILAND: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 117 MALAYSIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 118 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 119 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 120 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 121 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 122 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 123 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 124 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 125 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 126 MALAYSIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 127 PHILIPPINES: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 128 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 129 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 130 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 131 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 132 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 133 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 134 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 135 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 136 PHILIPPINES: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 137 VIETNAM: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 138 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 139 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 140 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 141 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 142 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 143 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 144 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 145 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 146 VIETNAM: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 147 SINGAPORE: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 148 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 149 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 150 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 151 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 152 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 153 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 154 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 155 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 156 SINGAPORE: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 157 MYANMAR: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 158 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 159 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 160 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 161 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 162 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 163 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 164 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 165 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 166 MYANMAR: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 167 CAMBODIA: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 168 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 169 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 170 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 171 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 172 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 173 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 174 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 175 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 176 CAMBODIA: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 177 LAOS: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 178 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 179 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 180 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 181 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 182 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 183 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 184 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 185 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 186 LAOS: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 187 BRUNEI: MACROECONOMIC INDICATORS FOR ASEAN POINT OF CARE DIAGNOSTICS MARKET
  • TABLE 188 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2022–2030 (USD MILLION)
  • TABLE 189 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY DISEASE TYPE, 2022–2030 (USD MILLION)
  • TABLE 190 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR RESPIRATORY INFECTION TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 191 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR HEPATITIS TESTING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 192 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR GLUCOSE MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 193 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR CARDIOMETABOLIC MONITORING PRODUCTS, BY TYPE, 2022–2030 (USD MILLION)
  • TABLE 194 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 195 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING PRODUCTS, BY TECHNOLOGY, 2022–2030 (USD MILLION)
  • TABLE 196 BRUNEI: ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2022–2030 (USD MILLION)
  • TABLE 197 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, JANUARY 2021−MARCH 2025
  • TABLE 198 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 199 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COUNTRY FOOTPRINT
  • TABLE 200 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT FOOTPRINT
  • TABLE 201 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TECHNOLOGY FOOTPRINT
  • TABLE 202 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 203 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY TECHNOLOGY
  • TABLE 204 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SMES, BY COUNTRY
  • TABLE 205 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 206 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 207 ASEAN POINT OF CARE DIAGNOSTICS MARKET: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 208 ABBOTT: COMPANY OVERVIEW
  • TABLE 209 ABBOTT: PRODUCTS OFFERED
  • TABLE 210 ABBOTT: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 211 ABBOTT: DEALS, JANUARY 2021– MARCH 2025
  • TABLE 212 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 213 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 214 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 215 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021– MARCH 2025
  • TABLE 216 SIEMENS HEALTHINEERS AG: COMPANY OVERVIEW
  • TABLE 217 SIEMENS HEALTHINEERS AG: PRODUCTS OFFERED
  • TABLE 218 SIEMENS HEALTHINEERS AG: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 219 SIEMENS HEALTHINEERS AG: DEALS, JANUARY 2021– MARCH 2025
  • TABLE 220 SIEMENS HEALTHINEERS AG: EXPANSIONS, JANUARY 2021– MARCH 2025
  • TABLE 221 SYSMEX CORPORATION: COMPANY OVERVIEW
  • TABLE 222 SYSMEX CORPORATION: PRODUCTS OFFERED
  • TABLE 223 SYSMEX CORPORATION: EXPANSIONS, JANUARY 2021−MARCH 2025
  • TABLE 224 DANAHER CORPORATION: COMPANY OVERVIEW
  • TABLE 225 DANAHER CORPORATION: PRODUCTS OFFERED
  • TABLE 226 BD: COMPANY OVERVIEW
  • TABLE 227 BD: PRODUCTS OFFERED
  • TABLE 228 BD: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 229 BD: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 230 QUIDELORTHO CORPORATION: COMPANY OVERVIEW
  • TABLE 231 QUIDELORTHO CORPORATION: PRODUCTS OFFERED
  • TABLE 232 QUIDELORTHO CORPORATION: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 233 QUIDELORTHO CORPORATION: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 234 QUIDELORTHO CORPORATION: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 235 CARDINAL HEALTH: COMPANY OVERVIEW
  • TABLE 236 CARDINAL HEALTH: PRODUCTS OFFERED
  • TABLE 237 CARDINAL HEALTH: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 238 CARDINAL HEALTH: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 239 BIOMÉRIEUX: COMPANY OVERVIEW
  • TABLE 240 BIOMÉRIEUX: PRODUCTS OFFERED
  • TABLE 241 BIOMÉRIEUX: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 242 BIOMÉRIEUX: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 243 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY OVERVIEW
  • TABLE 244 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCTS OFFERED
  • TABLE 245 EKF DIAGNOSTICS HOLDINGS PLC: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 246 EKF DIAGNOSTICS HOLDINGS PLC: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 247 EKF DIAGNOSTICS HOLDINGS PLC: EXPANSIONS, JANUARY 2021–MARCH 2025
  • TABLE 248 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 249 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 250 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES, JANUARY 2021–MARCH 2025
  • TABLE 251 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2021–MARCH 2025
  • TABLE 252 ACCUBIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 253 ACCUBIOTECH CO., LTD.: PRODUCTS OFFERED
  • TABLE 254 ACCUBIOTECH CO., LTD.: PRODUCT APPROVALS, JANUARY 2021–MARCH 2025
  • TABLE 255 BIOSYNEX SA: COMPANY OVERVIEW
  • TABLE 256 SD BIOSENSOR, INC.: COMPANY OVERVIEW
  • TABLE 257 SEKISUI DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 258 WERFEN: COMPANY OVERVIEW
  • TABLE 259 TRINITY BIOTECH: COMPANY OVERVIEW
  • TABLE 260 PTS DIAGNOSTICS: COMPANY OVERVIEW
  • TABLE 261 LIFESCAN IP HOLDINGS, LLC: COMPANY OVERVIEW
  • TABLE 262 CTK BIOTECH, INC.: COMPANY OVERVIEW
  • TABLE 263 WONDFO: COMPANY OVERVIEW
  • TABLE 264 ARKRAY, INC.: COMPANY OVERVIEW
  • TABLE 265 XIAMEN BOSON BIOTECH CO., LTD.: COMPANY OVERVIEW
  • TABLE 266 CREDO DIAGNOSTICS BIOMEDICAL PTE. LTD.: COMPANY OVERVIEW
  • TABLE 267 ANBIO BIOTECHNOLOGY INC.: COMPANY OVERVIEW
  • TABLE 268 SG DIAGNOSTICS: COMPANY OVERVIEW
LIST OF FIGURES
 
  • FIGURE 1 MARKETS COVERED & REGIONS CONSIDERED
  • FIGURE 2 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH DESIGN
  • FIGURE 3 ASEAN POINT OF CARE DIAGNOSTICS MARKET: KEY INDUSTRY INSIGHTS
  • FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE AND DESIGNATION
  • FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
  • FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
  • FIGURE 8 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TOP-DOWN APPROACH
  • FIGURE 9 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 10 ASEAN POINT OF CARE DIAGNOSTICS MARKET: RESEARCH ASSUMPTIONS
  • FIGURE 11 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION)
  • FIGURE 12 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY TECHNOLOGY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 13 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION)
  • FIGURE 14 ASEAN POINT OF CARE DIAGNOSTICS MARKET, BY COUNTRY, 2025 VS. 2030 (USD MILLION)
  • FIGURE 15 RISING PREVALENCE OF INFECTIOUS DISEASES TO PROPEL MARKET
  • FIGURE 16 GLUCOSE MONITORING PRODUCTS SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 17 BIOCHEMISTRY SEGMENT TO HOLD LARGEST MARKET SHARE TILL 2030
  • FIGURE 18 HOME CARE SETTINGS AND CLINICAL LABORATORIES TO ACCOUNT FOR MAJOR MARKET SHARES DURING FORECAST PERIOD
  • FIGURE 19 VIETNAM TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 20 ASEAN POINT OF CARE DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 21 ESTIMATES OF TB INCIDENCE FOR SOUTHEAST ASIA REGION, BY AGE GROUP AND GENDER (2023)
  • FIGURE 22 ASEAN POINT OF CARE DIAGNOSTICS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
  • FIGURE 23 ASEAN POINT OF CARE DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 24 ASEAN POINT OF CARE DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 25 ASEAN POINT OF CARE DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 26 INVESTMENT & FUNDING SCENARIO, 2021−2024
  • FIGURE 27 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PATENT ANALYSIS, JANUARY 2014–DECEMBER 2024
  • FIGURE 28 ASEAN POINT OF CARE DIAGNOSTICS MARKET: PORTER’S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TECHNOLOGY
  • FIGURE 30 KEY BUYING CRITERIA, BY TECHNOLOGY
  • FIGURE 31 ASEAN POINT OF CARE DIAGNOSTICS MARKET: POTENTIAL OF AI
  • FIGURE 32 ASEAN: POINT OF CARE DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2022–2024
  • FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS IN ASEAN POINT OF CARE DIAGNOSTICS MARKET, 2024
  • FIGURE 35 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 36 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 37 ASEAN POINT OF CARE DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 38 EV/EBITDA OF KEY VENDORS, 2025
  • FIGURE 39 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS, 2025
  • FIGURE 40 ASEAN POINT OF CARE DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON MATRIX
  • FIGURE 41 ABBOTT: COMPANY SNAPSHOT (2024)
  • FIGURE 42 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024)
  • FIGURE 43 SIEMENS HEALTHINEERS AG: COMPANY SNAPSHOT (2024)
  • FIGURE 44 SYSMEX CORPORATION: COMPANY SNAPSHOT (2023)
  • FIGURE 45 DANAHER CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 46 BD: COMPANY SNAPSHOT (2024)
  • FIGURE 47 QUIDELORTHO CORPORATION: COMPANY SNAPSHOT (2024)
  • FIGURE 48 CARDINAL HEALTH: COMPANY SNAPSHOT (2024)
  • FIGURE 49 BIOMÉRIEUX: COMPANY SNAPSHOT (2024)
  • FIGURE 50 EKF DIAGNOSTICS HOLDINGS PLC: COMPANY SNAPSHOT (2023)
  • FIGURE 51 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2024)

 

The study involved major activities in estimating the current market size for the ASEAN point of care diagnostics market. Exhaustive secondary research was done to collect information on the ASEAN point of care diagnostics industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as top-down and bottom-up, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the ASEAN point of care diagnostics market.

The four steps involved in estimating the market size are:

Secondary Research

In the secondary research process, various secondary sources, such as company annual reports, press releases, and investor presentations, white papers, certified publications, articles by recognized authors, gold-standard and silver-standard websites, regulatory bodies, and databases (such as D&B Hoovers, Bloomberg Business, and Factiva), were referred to identify and collect information for this study.

Primary Research

In the primary research process, various supply and demand sources were interviewed to obtain qualitative and quantitative information for this report. Primary sources were mainly industry experts from the core and related industries and preferred suppliers, manufacturers, distributors, service providers, technology developers, researchers, and organizations related to all segments of this industry’s value chain. In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts, C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative and quantitative information and assess prospects.

The following is a breakdown of the primary respondents:

Asean Point of Care Diagnostics Market

Note 1: Others include sales, marketing, and product managers.

Note 2: Companies are classified into tiers based on their total revenues. As of 2024, Tier 1 = >USD 100 million, Tier 2 = USD 10 million to USD 100 million, and Tier 3 = < USD 10 million.

To know about the assumptions considered for the study, download the pdf brochure

COMPANY NAME DESIGNATION
PTS Diagnostics Regional Sales Manager
EKF Diagnostics Holdings plc Product Manager

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the ASEAN point of care diagnostics market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry have been identified through extensive secondary research
  • Primary and secondary research has determined the revenues of leading players operating in the ASEAN point of care diagnostics market.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

The research methodology used to estimate the market size includes the following:

Asean Point of Care Diagnostics Market

Data Triangulation

After arriving at the overall market size by applying the abovementioned process, the total market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Point of care testing (POCT) includes tests designed to be used at or near the patient's site (such as at home, in an ambulance, at a physician’s office, and other locations). POCT allows rapid & reliable diagnostic testing to obtain outcomes instantly, helping physicians/patients make care decisions remotely and rapidly.

Stakeholders

  • Senior Management
  • End User
  • Finance/Procurement Department  
  • R&D Department

Report Objectives

  • To define, describe, segment, and forecast the ASEAN point of care diagnostics market based on product, technology, end user, and country
  • To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall ASEAN point of care diagnostics market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the market segments with respect to ten countries, namely, Vietnam, Laos, Cambodia, Malaysia, Myanmar, Philippines, Singapore, Thailand, Indonesia, and Brunei
  • To profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze company developments such as product launches & approvals, partnerships, acquisitions, agreements, and other developments
  • To benchmark players within the market using the proprietary Competitive Leadership Mapping framework, which analyzes market players on various parameters within the broad categories of business & product excellence

Previous Versions of this Report

ASEAN and North Asian Point of Care/Rapid Diagnostics Market by Product (Glucose Monitoring, COVID, HIV, STDs, HAIs, Influenza, Tropical & Respiratory diseases), Technique (Rapid test, Molecular diagnostics), User (Hospital, Home Care) - Forecast to 2026

Report Code MD 8010
Published in Nov, 2021, By MarketsandMarkets™
"Our USP is "providing game-changing business opportunities reports with free customization" - so please feel free to provide us with your specific areas of interest / business challenges in much greater detail !!"

We appreciate your interest in this report. Once you fill out the form, you'll be immediately directed to an exclusive solution tailored to your needs. This high-value offering can help boost your revenue by 30% - a must-see opportunity for anyone looking to maximize growth.


By clicking the "Submit" button, you are agreeing to the Terms of Use and Privacy Policy.

Custom Market Research Services

We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements

Get 10% Free Customisation

Growth opportunities and latent adjacency in ASEAN Point of Care Diagnostics Market

DMCA.com Protection Status